AZRX News and Press, AzurRx BioPharma Inc. From 09/15/20

Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis & Best Enteric Capsule for Targeted Duodenal Delivery of Non-Porcine ...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it wi...

AzurRx BioPharma ( AZRX ) announces that nine of the expected 15 clinical trial sites in the European arm of its Phase 2b OPTION 2 study are active and recruiting participants. The trial is evaluating MS1819 in 30 cystic fibrosis patients with exocrine pancreatic insufficiency. More ne...

Three clinical trial sites activated in Poland, with patient screening initiated Follows activation of six clinical sites in the U.S. and dosing of first three patients Topline data expected in Q1 2021 NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:A...

AzurRx BioPharma (NASDAQ: AZRX ) has enrolled the first three patients in its Phase 2b OPTION 2 clinical trial to investigate lead candidate MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency. More news on: AzurRx BioPharma, Inc., Healthcare stocks news, Re...

Newgioco Group (NASDAQ: NWGI )   -20%  on pricing equity offering. More news on: Newgioco Group, Inc., Vroom, Inc., Aegon N.V., Stocks on the move, , Read more ...

First three patients enrolled in dose escalation trial using delayed-release enteric capsules Topline data expected in 1H 2021 NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company speci...

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following let...

EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35%  on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...